A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

Randomized, Open-label, Single-dose, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of a Triple Fixed-dose Combination Tablet (Gemigliptin/Dapagliflozin/Metformin) 50/10/1000 mg and Co-administered Zemiglo (Gemigliptin) 50 mg and Xigduo XR (Dapagliflozin/Metformin) 10/1000 mg in Healthy Adult Subjects Under Fasting Conditions

Bioequivalence study for the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg under fasting conditions in healthy volunteers

Inclusion Criteria:

• Healthy adults between 19 and 50 years of age
• People with a body weight within a healthy range
• People who do not have serious medical conditions and have been generally healthy in recent years
• People whose screening tests (blood tests, urine tests, vital signs, ECG, etc.) show no significant abnormalities
• Women of childbearing potential must not be pregnant at screening
• Participants must agree to use reliable contraception or abstain from sexual activity during the study and for a short period after the last dose
• People who fully understand the study, agree to follow study requirements, and provide written informed consent

Exclusion Criteria:

• People with a history of significant diseases, such as heart, liver, kidney, lung, neurological, psychiatric, immune, or cancer-related conditions
• People with digestive diseases or surgeries that may affect how medicines are absorbed
• People with abnormal screening laboratory results, especially related to liver or kidney function
• People who drink large amounts of alcohol, use drugs, or smoke heavily
• People who have recently taken certain medications, herbal products, or dietary supplements that could interfere with the study
• People who have recently participated in another clinical trial, donated blood, or received a blood transfusion
• Pregnant or breastfeeding women
• People with unstable or serious health conditions that could increase risk or affect study results
• Anyone who, in the opinion of the study doctor, is not suitable to participate